发明名称 Novel derivatives of imidazolidine, method of obtaining such derivatives, their application in production of a pharmaceutic agent, pharmaceutic agent as such and method of obtaining a pharmaceutic agent
摘要 Imidazolidine derivatives (I) are new. Imidazolidine derivatives of formula (I) are new. W = R<1>-A-C(R<13>), R<1>-A-C(R<13>)=C or a group (i) or (ii), whose ring systems may contain one or two independent N, O or S heteroatoms and may optionally be mono- or polyunsaturated and/or be substituted by one or more independent R<13> groups or by 1 or 2 double-bonded O and/or S atoms; L = C(R<13>) or N; m1, m2 = 0-6 (provided that m1 + m2 = 1-6); Y = CO, C(=S) or CH2; A = a direct bond, 1-6C alkylene, 3-7C cycloalkylene, phenylene, phenylene-(1-6C alkyl), phenylene-(2-6C alkenyl) or a 5- or 6-membered optionally substituted heterocycle, provided that the phenylenealkyl and phenylenealkenyl groups are bound to R<1> via the aromatic ring; B = 1-6C alkylene, 2-6C alkenylene, phenylene, phenylene-(1-3C alkyl), (1-3C alkylene)-phenyl or (1-3C alkylene)-phenyl-(1-3C alkyl), where the 1-6C alkylene and 2-6C alkenylene groups are optionally substituted; E = tetrazolyl, (R<8>O)2P(O), R<10>OSO2, R<9>NHSO2, R<6>CO, R<7>CO, R<10>CO, CHO, R<8>O-CH2, R<8>CO-OCH2, R8aO-CO-O-CH2 or (R<8>O)2P(O)-O-CH2; R = H, 1-8C alkyl, 3-12C cycloalkyl, 3-12C cycloalkyl-1-8C alkyl, 6-14C aryl, 6-14C aryl-1-8C alkyl, heteroaryl or heteroaryl-1-8C alkyl (all aryl being optionally substituted); R<1> = H, 1-10C alkyl or fluoroalkyl, 3-12C cycloalkyl, 3-12C cycloalkyl-(1-8C alkyl), R<21>-(6-14C aryl), R<21>-(6-14C aryl)-(1-8C alkyl), Het, Het-(1-8C alkyl) or X-NH-C(=NH)R<20>, X<1>-NH-R<20>, R<21>-O-R<20>, R<21>N(R<21>)-R<20>, R<21>-CO, R<21>-O-CO, R<22>N(R<21>)CO, R<2>CO-N(R<21>), R<21>O-N=, O= or S=; X = H, 1-6C alkyl, (1-6C alkyl)carbonyl, (1-6C alkoxy)carbonyl, (1-10C alkyl)carbonyloxy-(1-6C alkoxy)carbonyl, optionally substituted 6-14C arylcarbonyl or aryloxycarbonyl, (6-14C aryl)-(1-6C alkoxy)carbonyl, CN, OH, 1-6C alkoxy, (6-14C aryl)-(1-6C alkoxy) or amino; X<1> = as for X or is R'-NH-C(=N-R''); R', R'' = as for X; R<2> = H, 1-8C alkyl, optionally substituted 6-14C aryl or (6-14C aryl)-(1-8C alkyl) or 3-8C cycloalkyl; R<3> = e.g. H, 1-10C alkyl or fluoroalkyl, optionally substituted 6-14C aryl, 6-14C aryl-(1-8C alkyl), heteroaryl or heteroaryl-(1-8C alkyl), R<11>NH, CON(CH3)R<4>, CONHR<4>, COOR<21>, COOR<15>, CON(CH3)R<15> or CONHR<15>; R<4> = H or optionally substituted 1-10C alkyl; R<5> = 6-14C aryl or 6-14C aryl-1-8C alkyl (both being optionally aryl substituted) or mono-or bicyclic 5-12 membered heterocyclic R<6> = an amino or imino acid, an optionally alkylated or arylalkylated azaamino acid or a di-, tri- or tetrapeptide which may be esterified, amidated or protected; R<7> = an N-bound 5-10 membered saturated mono- or polycyclic heterocycle which is optionally substituted; R<8> = H, 1-10C alkyl, or optionally substituted 6-14C aryl or 6-14C aryl-(1-8C alkyl); R8a = as for R8, but is not H; R<9> = H, aminocarbonyl, (1-10C alkyl)aminocarbonyl or (3-8C cycloalkyl)aminocarbonyl; R<10> = e.g. OH, 1-10C alkoxy, 6-14C aryl-(1-8C alkoxy) or 6-14C aryloxy, or (R<8>)2NCO-(1-6C alkoxy)(the aryl groups in R<10> may all be substituted); R<11> = H, R12a, R12aCO, CHO, R12a-OCO, R12b-CO, R12b-C(=S), R12a-SO2 or R12b- SO2; R12a = 1-10C alkyl, 2-8C alkenyl, 2-8C alkynyl, 3-12C cycloalkyl, 3-12C cycloalkyl-(1-8C alkyl), 6-14C aryl, 6-14C aryl-(1-8C alkyl), heteroaryl or heteroaryl-(1-8C alkyl), where the aromatic groups are optionally substituted; R12b = NH2, di(1-10C alkyl)amino or R12a-NH; R<13> = H, 1-6C alkyl or fluoroalkyl, 6-14C aryl, 6-14C aryl-(1-6C alkyl), 3-8C cycloalkyl or 3-8C cycloalkyl-(1-6C alkyl), where the aromatic groups are optionally substituted; R<15> = R<16>-(1-6C alkyl) or R<16>; R<16> = 6-24 membered bi- or tricyclic group containing up to 4 N, O or S heteroatoms which is optionally substituted by 1-4C alkyl or oxo; R<21> = H, 1-8C alkyl, 3-12C cycloalkyl, 3-12C cycloalkyl-(1-8C alkyl), 6-14C aryl, 6-14C aryl-(1-8C alkyl), Het or Het-(1-8C alkyl), where the alkyl groups are optionally fluorinated and the aryl groups are optionally substituted; R<22> = R<21>, R<21>O, R<21>N(R<21>), R<21>CO, R<21>O-CO, R<21>N(R<21>)-CO, R<21>N(R<21>)-C(=N(R<21>)) or R<21>-CO-N(R<21>); R<30> = e.g. R<32)<R)N-CO-N(R)-R<31>, R<32)<R)N-C(=S)-N(R)-R<31>, R<32>-S(O)n-R<31> or R12a-OCO-N(R)-R<31>; provided that R<30> is not R<32>-CO-R<31> when W = R<1>-A-C(R<13>), A is a direct bond and R<1> and R<13> are H; R<31> = R<33>-R<34>-R<35>-R<36>, where the R<36> is bound to the imidazolyl group on (I); R<32> = H, 1-8C alkyl or fluoroalkyl, 2-8C alkenyl, 2-8C alkynyl, 3-12C cycloalkyl, 3-12C cycloalkyl-(1-8C alkyl), 6-12C bicycloalkyl, 6-12C bicycloalkyl-(1-8C alkyl), 6-12C tricycloalkyl, 6-12C tricycloalkyl-(1-8C alkyl), 6-14C aryl, heteroaryl or heteroaryl-(1-8C alkyl), where the aryl and heteroaryl groups are optionally substituted; R<20>, R<33> = a direct bond or 1-6C alkylene; R<34> = 1-8C alkylene, 3-12C cycloalkylene, 6-12C bicycloalkylene, 6-12C tricycloalkylene, or optionally substituted 6-14C arylene or heteroarylene; R<35> = a direct bond or 1-8C alkylene; R<36> = a direct bond, CO or S(O)n; Het = 4-14 membered mono- or polycyclic aromatic or non-aromatic ring which contains 1-4 N, S or O heteroatoms and is optionally substituted; e,h = 0 or 1; n = 1 or 2. A full set of definitions is given in the DEFINITIONS (Full Definitions) field. An Independent claim is also included for preparation of (I).
申请公布号 PL194692(B1) 申请公布日期 2007.06.29
申请号 PL19980329790 申请日期 1998.11.19
申请人 SANOFI-AVENTIS DEUTSCHLAND GMBH 发明人 WEHNER VOLKMAR;STILZ HANS ULRICH;SCHMIDT WOLFGANG;SEIFFGE DIRK
分类号 C07D233/54;C07D233/72;A61K31/00;A61K31/4164;A61K38/05;A61K38/06;A61K38/07;A61P1/00;A61P3/00;A61P3/10;A61P9/00;A61P9/10;A61P11/00;A61P11/06;A61P19/00;A61P19/02;A61P29/00;A61P29/02;A61P33/00;A61P33/06;A61P35/00;A61P37/00;A61P37/02;A61P37/06;A61P37/08;A61P43/00;C07D233/40;C07D233/74;C07D233/76;C07D405/12;C07K5/02;C07K5/023;C07K5/06;C07K5/072;C07K5/078;C07K5/093;C07K5/097;C07K5/107;C07K5/117 主分类号 C07D233/54
代理机构 代理人
主权项
地址